Executive Order Directs CDC to Reduce Number of Recommended Childhood Vaccines
On May 29, 2026, President Trump signed an executive order titled “Realigning United States Core Childhood Vaccine Recommendations With Best Practices from Peer, Developed Countries” endorsing a scientific assessment done earlier this year by the U.S. Department of Health and Human Services (DHHS) calling for a reduction in the number of recommended vaccines for children […]
ACIP Majority Ignores Risks and Recommends Infants Get Merck’s RSV Monoclonal Antibody
On June 25, 2025, the majority of members of the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ignored risk warnings and voted for a recommendation that infants be given Merck & Co.’s monoclonal antibody, clesrovimab, marketed as Enflonsia. The committee advised using Enflonsia to prevent Respiratory Syncytial Virus […]
Moderna Withdraws Application for Combination COVID and Flu Vaccine
Moderna, Inc. withdrew its application for United States licensure for its combination COVID-19/Influenza vaccine known as mRNA-1083. The company stated the decision came “in consultation with” the U.S. Food and Drug Administration (FDA).1 The decision came just one day after the FDA announced the agency would require new clinical trials for approval of annual COVID […]
Flu Shot Recipients “More Likely” to Get Influenza Than Unvaccinated
The American Medical Association (AMA) cites that the influenza vaccine is estimated to be 40-60 percent effective at preventing serious infections or death from the influenza virus that affects up to 40 million Americans every year. However, for the 2024-2025 flu “season” the influenza vaccine not only missed the mark on effectiveness, but is linked […]
FDA Requires RSV Vaccine Labels to Include Guillain-Barré Syndrome Risk
On Jan. 7, 2025, the U.S. Food and Drug Administration (FDA) mandated and approved changes to the safety labeling for the Prescribing Information of two Respiratory Syncytial Virus (RSV) vaccines: Abrysvo (manufactured by Pfizer)1 and Arexvy (manufactured by GlaxoSmithKline Biologicals).2 This label change update is being required to inform both the public and health care […]
Moderna Halts RSV Pediatric Vaccine Trial After Five Infants Hospitalized
On Dec. 11, 2024, the U.S. Food and Drug Administration (FDA) announced that clinical trials for Moderna’s pediatric mRNA RSV vaccines have been paused due to safety concerns. The recent phase 1 trials of two experimental respiratory syncytial virus (RSV) vaccines for infants not only failed to provide adequate protection but may have worsened respiratory […]